Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies
Open accessThe DOI matches its Crossref record.
Abstract
INTRODUCTION: This analysis was conducted to assess the tolerability, safety, and efficacy of brivaracetam (BRV) for adjunctive treatment of focal (partial-onset) seizures in patients aged ≥65 years. METHODS: Safety/tolerability and efficacy data for patients aged ≥65 years were pooled from three randomized, double-blind, placebo-controlled, fixed-dose Phase III studies (NCT00490035, NCT00464269, and NCT01261325). Data were pooled by treatment group: placebo or the proposed therapeutic dose range of 50-200 mg/day: BRV 50, 100, 200mg/day. RESULTS: Thirty-two patients aged ≥65 years were randomized to placebo or BRV 50-200 mg/day. Of these, 30 patients (93.8%) completed their respective study. In the safety population (n=32), 87.5% placebo- vs 73.3% BRV-treated patients reported treatment-emergent adverse events (TEAEs) during the treatment period; most commonly, headache (25.0% vs 12.5%), paresthesia (0% vs 12.5%), and somnolence (50.0% vs 12.5%) for placebo- vs BRV-treated patients, respectively. During the treatment period, drug-related TEAEs were reported by 62.5% of placebo- vs 53.3% of BRV-treated patients, and serious TEAEs (SAEs) were reported by 0% of placebo- and 4.2% of BRV-treated patients; there were no drug-related SAEs and no deaths. Three SAEs (placebo 1/8; BRV 2/24) and two deaths (placebo 1/8; BRV 1/24) occurred in the post-treatment period. In the efficacy population (n=31), median percent reduction from baseline in focal seizure frequency/28days was 14.0% for placebo vs 25.5%, 49.6%, and 74.9% for BRV 50, 100, and 200 mg/day, respectively. The ≥50% responder rate was 14.3% for placebo vs 25.0%, 50.0%, and 66.7% for BRV 50, 100, and 200 mg/day, respectively. CONCLUSIONS: Safety/tolerability and efficacy findings in this small subgroup of older patients treated with adjunctive BRV are consistent with those observed in the much larger overall pooled population. BRV may be a suitable adjunctive treatment for older patients with uncontrolled focal seizures. Further larger studies in this population are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
“Special populations Elderly patients Data from patients aged ≥65 years in the pivotal Phase III studies were pooled to assess the safety and efficacy of BRV 50–200 mg/day in elderly patients (n=32).(104) Findings were consistent with those of the overall patient population.”
ResultSelf-citationKlein, P., & Bourikas, D. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02876-z · Cited by 21
“A post hoc analysis of the pooled phase III trials assessed safety, tolerability, and efficacy of adjunctive BRV (50–200 mg/day) in older patients ≥ 65 years of age ( n = 32) [58].”
MethodA brief review on efficacy and safety of brivaracetam in the management of partial onset epilepsy
Vithoba Panchal, G., & Nath Mishra, V. (2021) · IP Indian Journal of Neurosciences · doi:10.18231/j.ijn.2021.017 · Cited by 2
Metadata
- Authors
- Brodie, M. J., Whitesides, J., Schiemann, J., D’Souza, J., & Johnson, M. E.
- Venue
- Epilepsy Research
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 127
- Pages
- 114-118
- ISSN
- 0920-1211 (ISSN-L)
- OpenAlex
- W2518276265
- Cited by
- 37
- References
- 0
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. https://app.cochat.ai/papers/10.1016/j.eplepsyres.2016.08.018
- The paper
- Brodie, M. J., Whitesides, J., Schiemann, J., D’Souza, J., & Johnson, M. E. (2016). Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. Epilepsy Research. https://doi.org/10.1016/j.eplepsyres.2016.08.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.